If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding PML is critical. This condition, while rare, requires prompt recognition and action. Building on decades of research into immune-mediated therapies, this page explains the signs of PML, how it is diagnosed, and what monitoring strategies are recommended.
Building on the foundation of general health awareness, we now turn to a specific therapeutic context where risk assessment is critical. Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The prognosis for patients who develop PML from Tysabri is poor, with the condition often leading to permanent disability or death. The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and post-marketing surveillance. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks, and these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The question of whether PML from Tysabri is permanent is addressed by the clinical course of the disease. PML is caused by the JC virus, which typically only causes disease in immunocompromised individuals. The infection leads to progressive damage to the white matter of the brain, resulting in neurological deficits. The FDA label states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). While some patients may survive with aggressive management, including plasma exchange to remove Tysabri from the bloodstream and immune reconstitution, the neurological damage is often irreversible. Survivors frequently experience permanent deficits such as cognitive impairment, motor dysfunction, or vision loss. Therefore, for most affected patients, PML is a permanent condition with lasting effects.
Several risk factors increase the likelihood of developing PML in Tysabri-treated patients. These include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA label emphasizes that these factors should be considered when initiating and continuing treatment with Tysabri. The presence of anti-JCV antibodies indicates prior exposure to the JC virus, which is a prerequisite for PML. Longer treatment duration increases the cumulative risk, with the highest risk observed after two years of therapy. Prior immunosuppressant use may further compromise the immune system, making patients more susceptible to JC virus reactivation. The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML has also been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. The FDA label advises that patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that the risk of PML persists even after stopping the drug, and the onset of symptoms can be delayed.
The adequacy of warnings regarding Tysabri and PML is addressed by the FDA's boxed warning and the restricted distribution program. The boxed warning clearly states the risk of PML and the factors that increase it. Additionally, Tysabri is available only through the TOUCH Prescribing Program, a restricted distribution program designed to ensure that patients are monitored for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program requires healthcare providers to educate patients about the risk of PML, perform regular monitoring, and report any suspected cases. While these measures are comprehensive, the prognosis for patients who develop PML remains poor, highlighting the importance of early detection and intervention. For patients who develop PML, prognosis-related considerations include the need for immediate discontinuation of Tysabri and supportive care. The FDA label instructs healthcare professionals to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early diagnosis through MRI and cerebrospinal fluid analysis for JC virus DNA is critical. Treatment options are limited and focus on immune reconstitution, often through plasma exchange to accelerate Tysabri clearance. However, even with prompt intervention, many patients experience permanent neurological deficits. The FDA label notes that PML usually leads to death or severe disability, underscoring the gravity of this adverse event.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Yes, for most patients, PML from Tysabri results in permanent neurological damage. While some patients may survive with aggressive treatment, the neurological deficits are often irreversible, leading to lasting disability such as cognitive impairment, motor dysfunction, or vision loss. The FDA label states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Key risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors increase the likelihood of JC virus reactivation and PML development.
Yes, PML has been reported after discontinuation of Tysabri in patients who did not have symptoms at the time of stopping. The FDA advises monitoring for new signs or symptoms suggestive of PML for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.